Study evaluating the impact of a combination of inotropic support and heart rate monitoring on prognosis and stabilization rate in patients with decompensated chronic heart failure (LEGION)
- Authors: Arutyunov G.P.1, Arutyunov A.G.1, Volkova A.L.2, Arutyunov GP2, Arutyunov AG2, Volkova on behalf of the task group AL2
-
Affiliations:
- ГОУ ВПО РГМУ Росздрава
- Городская клиническая больница № 4
- Issue: Vol 82, No 3 (2010)
- Pages: 47-52
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30564
- ID: 30564
Cite item
Full Text
Abstract
Subjects and methods. The study enrolled 41 patients (20 men and 21 women) aged 61 ± 9 years, admitted for decompensated heart failure (NYHA functional class IV). Ejection fraction averaged 21.6%. In most patients, systolic blood pressure was below 105 mm Hg and heart rate (HR) was 100-115 beats/min. Central hemodynamics was measured using the strip tests. The patients' clinical status was rated applying the scale accepted in Russia. In addition to conventional therapy, Group 1 patients received levosimendan and ivabradine and Group 2 took dopamine after randomization.
Results. A significantly more pronounced clinical improvement was noted in Group 1 patients at hours 48 and 72 of determination. There was a significantly more marked HR reduction in Group 1 at 24 and 72 hours of observation. By day 3 of observation, pulmonary wedge pressure was significantly lower in Group 1 than in Group 2. In the same control periods, the increase in coronary perfusion pressure was significantly obvious in Group 1. The drastically increased level of N-terminal fragment of the prohormone brain-type natriuretic peptide was significantly reduced in both groups, but more considerably in Group 1.
Conclusion. In patients with decompensated heart failure on conventional therapy, the co-administration of levosimendan and ivabradine is more effective than the use of dopamine.
Keywords
About the authors
Grigoriy Pavlovich Arutyunov
ГОУ ВПО РГМУ Росздрава
Email: arut@ossn.ru
Кафедра терапии Московского факультетапроф., д-р мед. наук, зав. каф; ГОУ ВПО РГМУ Росздрава
Aleksandr Grigor'evich Arutyunov
ГОУ ВПО РГМУ РосздраваКафедра терапии Московского факультетаассистент; ГОУ ВПО РГМУ Росздрава
Anna Leonidovna Volkova
Городская клиническая больница № 4врач отд-ния кардиореанимации; Городская клиническая больница № 4
G P Arutyunov
A G Arutyunov
A L Volkova on behalf of the task group
References
- Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность ХСН в европейской части Российской Федерации - данные Эпоха ХСН. Сердеч. недостат. 2006; 7(1): 4-7.
- Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Даниелян М. О. Первые результаты национального эпидемиологического исследования - эпидемиологическое обследование больных ХСН в реальной практике (по обращаемости) - ЭПОХА-О-ХСН. Сердеч. недостат. 2003; 4(3): 116-121.
- The Task Force for the Diagnosis and Treatment of chronic Heart Failure of the European Society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005; 26(11): 1115-1140.
- Cowie M. R., Mosterd A., Wood D. A. et al. The epidemiology of heart failure. Eur. Heart J. 1997; 18: 208-225.
- Innes C. A., Wagstaff A. J. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003; 63(23): 2651-2671.
- Munger M. A. Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy 2006; 26(8, Pt 2): 131S-138S.
- Сычева И. М., Виноградов А. В. Хроническая недостаточность кровообращения. М.: Медицина; 1977.
- Remme W. J., Torp-Pedersen C., Cleland J. G. et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J. Am. Coll. Cardiol. 2007; 49(9): 963-971.
- Nieminen M. S., Akkila J., Hasenfuss G. et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. 2000; 36(6): 1903-1912.
- Fonarow G. C., Adams K. F. Jr., Abraham W. T. for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure Classification and Regression Tree Analysis. J. A. M. A. 2005; 293: 572-580.
- Fonarow G. C., Heywood J. T., Heidenreich P. A. et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am. Head J. 2007; 153(6): 1021-1028.
- Silvers S. M., Howell J. M., Kosowsky J. M. et al American College of Emergency Physicians Clinical Policies Subcommittee. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann. Emerg. Med. 2007; 49(5): 627-669.
- Metra M., Torp-Pedersen C., Cleland J. G.et al. COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur. J. Heart Fail. 2007; 9(9): 901-909.
- Purcell H., Mach F. Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine. Rev. Med. Suisse 2007; 3(113): 1375-1378, 1381-1382.
- Petersen J. W., Felker G. M. Inotropes in the management of acute heart failure. Crit. Care Med. 2008; 36(1; Suppl.): S106-S111.
- Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin. Pharmacother. 2006; 7(16): 2179-2202.
- The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997; 336(8): 525-533.
- Sukonthasarn A. Prognostic value of heart rate in cardiovascular disease. J. Med. Assoc. Thailand 2007; 90(11): 2538-2540.
- Kudaiberdieva G., Görenek B., Timuralp B. Heart rate variability as a predictor of sudden cardiac death. Anadolu Kardiyol. Derg. 2007; 7(Suppl. 1): 68-70.
- Thackray S., Easthaugh J., Freemantle N., Cleland J. G. F. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur. J. Heart Fail. 2002; 4: 515-529.
- Giannakoulas G., Giannoglou G., Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am. J. Cardiol. 2006; 98(8): 1123-1124.
- Lucats L., Ghaleh B., Colin P. et al. Free in PMC Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening. Br. J. Pharmacol. 2007; 150(3): 335-341.
- Cleland J. G., Freemantle N., Coletta A. P., Clark A. L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 2006; 8(1): 105- 110.
- Yilmaz M. B., Yalta K., Yontar C. et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc. Drugs Ther. 2007; 21(6): 431-435.